The abstract is read at the publisher; the summary is JClub's.
Two different EGFR germline variants were found in three NSCLC patients, and cis compound expression showed oncogenic activity with sensitivity to afatinib.
- Why it matters: Hereditary risk factors for NSCLC are not well defined, and accurate functional interpretation of rare EGFR germline changes is limited for risk assessment and therapy planning.
- What they did: Germline WGS in Task Force 5 of the German National Network for Genomic Medicine identified EGFR variants, which were evaluated by in silico structural modeling and in vitro Ba/F3 assays for oncogenic potential and TKI sensitivity.
- The result: In silico modeling linked p.(Gly719Ser) and p.(Gly719Ala) to stabilization of the active kinase state, while p.(Ser768Ile), p.(Arg776His), and p.(Leu861Gln) destabilized the inactive state; Ba/F3 cis co-expression showed oncogenic activity and afatinib sensitivity, and two patients achieved partial response to afatinib.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.